Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ng » 100 ng (Expand Search), 10 mg (Expand Search), 10 nm (Expand Search)
Showing 121 - 140 results of 78,256 for search '(((( 2 e decrease ) OR ( 5 ((mean decrease) OR (a decrease)) ))) OR ( 10 ng decrease ))', query time: 1.15s Refine Results
  1. 121
    Diabetic wounds show increased amounts of vessel leakage and decreased pericyte coverage.

    Diabetic wounds show increased amounts of vessel leakage and decreased pericyte coverage. by Uzoagu A. Okonkwo (8754933)

    Published 2020
    Save to List
    Saved in:
  2. 122
    JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains.

    JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains. by Jihoon Jeong (4852690)

    Published 2020
    Save to List
    Saved in:
  3. 123
    WT data of set A398E/V and set M1425V/I pooled for better comparison.

    WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 124
    Experiments validate that small spaces decrease fitness difference across different abundances.

    Experiments validate that small spaces decrease fitness difference across different abundances. by Raymond Copeland (17854736)

    Published 2024
    Save to List
    Saved in:
  5. 125
    Downregulation of DOM decreases the abundance of PER and TIM.

    Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

    Published 2019
    “…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
    Save to List
    Saved in:
  6. 126
    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR.

    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  7. 127
    DENV infection decreases <i>AGPAT1</i> but not <i>AGPAT2</i> expression.

    DENV infection decreases <i>AGPAT1</i> but not <i>AGPAT2</i> expression. by Thomas Vial (5896886)

    Published 2019
    Save to List
    Saved in:
  8. 128
    Decrease of Sun4 protein level upon <i>eIF2A</i> overexpression requires the presence of Ssd1.

    Decrease of Sun4 protein level upon <i>eIF2A</i> overexpression requires the presence of Ssd1. by Laura Meyer (4033793)

    Published 2023
    Save to List
    Saved in:
  9. 129
    SUR1Δ/LDLR<sup>-/-</sup> mice have increased fasting glucose levels and impaired glucose tolerance with decreased insulin secretion.

    SUR1Δ/LDLR<sup>-/-</sup> mice have increased fasting glucose levels and impaired glucose tolerance with decreased insulin secretion. by Erika Gurzeler (4781904)

    Published 2021
    Save to List
    Saved in:
  10. 130
    Scientists’ likelihood of using terminology sorted by overall decreasing likelihood ranking.

    Scientists’ likelihood of using terminology sorted by overall decreasing likelihood ranking. by Jackie M. Getson (13190175)

    Published 2022
    Save to List
    Saved in:
  11. 131
    The decreased permeability caused by phospholipid content in the membrane could drive the emergence of other functions in the protocells.

    The decreased permeability caused by phospholipid content in the membrane could drive the emergence of other functions in the protocells. by Wentao Ma (326530)

    Published 2025
    Save to List
    Saved in:
  12. 132
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 133
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 134
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 135
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 136
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 137
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 138
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 139
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 140
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: